Instil Bio (TIL) announced the addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Instil’s wholly-owned subsidiary dedicated to the development of AXN-2510, a potentially best-in-class PD-L1xVEGF bispecific antibody for solid tumors prioritizing front-line non-small cell lung cancer
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIL: